FY2024 · ended Dec 31, 2025 · Revenue $170,000, -83.0% YoY · Filed Mar 12, 2026
Lisata Therapeutics, Inc. (LSTA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2024, which ended Dec 31, 2025, it reported revenue of $170,000 and a net loss of $16.6 million. Free cash flow was -$16.0 million.
Revenue
$170,000
-83.0% vs prior year
Net income
$-16.59M
+17.0% vs prior year
Operating cash flow
$-15.95M
+17.6% vs prior year
Free cash flow
$-15.98M
+20.2% vs prior year
EPS
$-1.91
+20.4% vs prior year
Dividend per share
None
Shares outstanding
9.11M
+0.8% vs prior year
Net cash
$27.60M
FY 2024
Operating margin
-10711.2%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LSTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Basking Ridge, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 320017
- Former names
- Caladrius Biosciences, Inc. (until Sep 15, 2022); CALADRIUS BIOSCIENCES, INC. (until Sep 15, 2022); NeoStem, Inc. (until Jun 5, 2015); PHASE III MEDICAL INC/DE (until Sep 1, 2006); CORNICHE GROUP INC /DE (until Aug 14, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $170,000 | $1.0M | $0 | — | — |
| Operating income | -$18.2M | -$22.4M | -$25.7M | -$57.6M | -$29.1M |
| Net income | -$16.6M | -$20.0M | -$20.8M | -$54.2M | -$27.5M |
| Diluted EPS | -$1.91 | -$2.40 | -$2.58 | -$10.47 | -$7.45 |
| Operating cash flow | -$15.9M | -$19.4M | -$20.0M | -$21.2M | -$22.2M |
| Free cash flow | -$16.0M | — | -$20.0M | -$21.5M | -$22.3M |
| Total assets | $17.7M | $35.0M | $54.7M | $73.0M | $97.0M |
| Total liabilities | $3.1M | $5.7M | $6.8M | $6.7M | $5.0M |
| Stockholders' equity | $14.9M | $29.6M | $48.1M | $66.6M | $92.3M |
| Cash and investments | $27.6M | $41.9M | $67.2M | $96.9M | $116.1M |
| Total debt | $0 | $137,000 | $305,000 | $485,000 | $714,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 19, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Sep 17, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Agreement ended, Other events
|
Jul 24, 2026 | Jul 24, 2026 |
All 1001 Lisata Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.